Author Archives: Nisha Cooch, PhD

The beginning of fall has seen a steady stream of new data elucidating SMA mechanisms, as well as options for managing and treating the disease. There have also been reports of evolving efforts to optimize both SMA research and clinical care, such as through a new SMA registry and the…

Summer has closed with new data and news on SMA coming to the fore. Much of the research on SMA published in recent weeks has focused on how to best treat the disease, and some new debate has emerged surrounding the relative advantages of Zolgensma versus Spinraza. At the same…

Summer is closing with an abundance of new data on SMA. Studies aimed at understanding the disease process continue to provide information on its underlying mechanisms. At the same time, careful investigations of therapeutics are highlighting the potential of these interventions and identifying critical questions for future research, as well…

In July, the literature pertaining to spinal muscular atrophy (SMA) has focused mainly on understanding the disease. Information on treatments has been published largely in review form, while there has also been some new information on managing the disease and what having the disease means for patients.  Here is…

Over the past couple of weeks, there have been several new publications regarding spinal muscular atrophy (SMA) treatment. There has also been continued work in the basic science that aims to provide more understanding of the disease as well as research providing information relevant for the management of SMA. …

Since our last roundup, there has been continued focus in the spinal muscular atrophy (SMA) literature how best to treat the disease. There also continues to be research geared toward understanding the biology of the disease, as well as on SMA management, what it is like to live with the…

Much of the most recent research regarding spinal muscular atrophy (SMA) has focused on understanding the mechanisms mediating the disease as well as the clinical value of different pharmaceutical interventions. There have been several reviews on the latter topic, with a continuing emphasis on nusinersen, the first drug approved to…